Low Neuropeptide Y Levels Predict Who Will Develop Lasting Nerve Pain After Shingles | Research

The takeaway

Low plasma neuropeptide Y levels combined with clinical factors (age, acute pain severity, rash area) predicted postherpetic neuralgia with an AUC of 0.873, significantly better than clinical factors alone (0.804).

AUC 0.873 combined prediction
Adding NPY levels to clinical factors (age, pain severity, rash area) improved postherpetic neuralgia prediction from 80.4% to 87.3% accuracy

What the researchers found

Low plasma NPY levels independently predicted PHN development in 182 herpes zoster patients, and combining NPY with clinical factors (age, pain severity, rash area) improved predictive accuracy from AUC 0.804 to 0.873.

Why it matters

PHN causes chronic debilitating pain that's extremely difficult to treat once established. Being able to predict which shingles patients will develop PHN could allow doctors to intervene early with aggressive pain management and potentially prevent the condition from becoming chronic.

The numbers in context

182 patients studied between February 2022 and December 2023. Plasma NPY combined with clinical factors for prediction model.

How the study worked

Prospective cohort study (Feb 2022-Dec 2023). 182 herpes zoster patients and 38 healthy controls. NPY, BDNF, and NGF measured within 3 days of healing. 59 patients developed PHN. Logistic regression identified independent predictors. AUC analysis compared clinical factors alone vs. combined with NPY levels.

Who was studied

Herpes zoster patients, followed for postherpetic neuralgia development

What this study cannot tell us

Single-center study with moderate sample size (182 patients). NPY levels were measured at one time point — serial measurements might improve prediction. The optimal NPY cutoff for clinical decision-making is not established. Other biomarkers beyond NPY, BDNF, and NGF may also contribute to prediction. Whether early intervention guided by NPY testing actually prevents PHN requires a separate interventional study.

How to read the evidence

Moderate evidence from a prospective cohort study with 182 patients and proper biomarker validation statistics. The AUC improvement is clinically meaningful but external validation in other populations is needed.

When this study was published

Published in 2024, with data collected 2022-2023, reflecting current clinical practice for herpes zoster management.

The bigger picture

NPY is a neuropeptide with well-established roles in pain modulation, stress response, and neuroprotection. Its role as a biomarker for PHN risk makes biological sense — lower NPY levels may indicate impaired pain-suppression capacity, making the nervous system more vulnerable to developing chronic pain after shingles. This adds to a growing trend of using biomarkers to personalize pain medicine.

Questions still open

Could early NPY-guided intervention (aggressive pain management at initial shingles diagnosis) prevent PHN development?
Do NPY levels change during the course of shingles, and would serial measurements improve prediction?
Could NPY supplementation or receptor agonists be used therapeutically to prevent PHN?

Common questions

What is postherpetic neuralgia and why is it so hard to treat?

Postherpetic neuralgia (PHN) is chronic nerve pain that persists after a shingles rash heals — sometimes lasting months or years. The virus damages nerve fibers during the acute infection, and in some patients, this damage leads to persistent abnormal pain signaling. Once established, PHN is notoriously difficult to treat — many patients don't respond adequately to available medications. That's why predicting who will develop it (so you can intervene early) is so valuable.

What does neuropeptide Y do in pain control?

Neuropeptide Y (NPY) is a natural pain-suppressing molecule in the nervous system. It works by dampening pain signals in the spinal cord and brain. Lower NPY levels mean your nervous system has less ability to naturally suppress pain — potentially explaining why some shingles patients develop chronic pain while others don't. People with lower NPY may lack sufficient 'pain braking' capacity to prevent acute shingles pain from becoming chronic.

Read the original research

Validity of Plasma Neuropeptide Y in Combination with Clinical Factors in Predicting Neuralgia Following Herpes Zoster.

International journal of general medicine, 17, 4805-4814

View on PubMed ↗Publisher’s paper ↗

Citation

Wu, Dan; Li, Fang; Yang, Feifei; Liu, Jun. (2024). Validity of Plasma Neuropeptide Y in Combination with Clinical Factors in Predicting Neuralgia Following Herpes Zoster.. International journal of general medicine, 17, 4805-4814. https://doi.org/10.2147/IJGM.S480411